Zenas BioPharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZBIO Nasdaq 2836 zenasbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zenas BioPharma, Inc.

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 16th, 2026 2:15 pm
Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News - Jan 12th, 2026 11:09 pm
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Jan 7th, 2026 4:46 am
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study - Jan 6th, 2026 9:18 am
Wall Street Consolidates, Driving Muted Premarket Action for US Equity Futures - Jan 6th, 2026 7:16 am
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win - Jan 6th, 2026 4:25 am
How Much Could Obexelimab’s Phase 3 Win Reshape Zenas BioPharma’s (ZBIO) Autoimmune Franchise Ambitions? - Jan 6th, 2026 1:06 am
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. - Jan 5th, 2026 2:20 pm
Top Midday Decliners - Jan 5th, 2026 12:00 pm
US Equity Futures Mixed Pre-Bell Monday Despite Oil Sector Surge - Jan 5th, 2026 6:51 am
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - Jan 5th, 2026 5:05 am
Zenas shares crash after top drug misses expectations in immune disease study - Jan 5th, 2026 4:26 am
Sector Update: Health Care Stocks Higher Late Afternoon - Dec 22nd, 2025 1:58 pm
Sector Update: Health Care Stocks Higher in Afternoon Trading - Dec 22nd, 2025 11:55 am
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says - Dec 22nd, 2025 9:59 am
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 19th, 2025 2:15 pm
Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Dec 16th, 2025 1:10 am
Zenas BioPharma Says Partner InnoCare's Phase 2b Orelabrutinib Study in Systemic Lupus Erythematosus Meets Primary Endpoint - Dec 15th, 2025 6:45 am
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - Dec 15th, 2025 5:05 am
Huge Insider Buying in MGM and Salesforce - Dec 12th, 2025 7:45 am